These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18395459)

  • 61. Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease transgenic mice.
    Orr AL; Huang S; Roberts MA; Reed JC; Li S; Li XJ
    J Biol Chem; 2008 Jun; 283(23):16027-36. PubMed ID: 18400759
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
    Mo C; Renoir T; Hannan AJ
    Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice.
    Hannan AJ; Ransome MI
    J Neuroendocrinol; 2012 Feb; 24(2):341-56. PubMed ID: 21988129
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models.
    Tebbenkamp AT; Xu G; Siemienski ZB; Janus C; Fromholt SE; Brown HH; Swing D; Tessarollo L; Borchelt DR
    J Huntingtons Dis; 2014; 3(1):73-86. PubMed ID: 25062766
    [TBL] [Abstract][Full Text] [Related]  

  • 65. α-Synuclein levels modulate Huntington's disease in mice.
    Corrochano S; Renna M; Carter S; Chrobot N; Kent R; Stewart M; Cooper J; Brown SD; Rubinsztein DC; Acevedo-Arozena A
    Hum Mol Genet; 2012 Feb; 21(3):485-94. PubMed ID: 22010050
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
    Vamos E; Voros K; Zadori D; Vecsei L; Klivenyi P
    J Neural Transm (Vienna); 2009 Sep; 116(9):1079-86. PubMed ID: 19551467
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease.
    Andreassen OA; Ferrante RJ; Huang HM; Dedeoglu A; Park L; Ferrante KL; Kwon J; Borchelt DR; Ross CA; Gibson GE; Beal MF
    Ann Neurol; 2001 Jul; 50(1):112-7. PubMed ID: 11456300
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
    Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
    Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
    Dufour BD; McBride JL
    Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Exosomes as a potential messenger unit during heterochronic parabiosis for amelioration of Huntington's disease.
    Lee M; Im W; Kim M
    Neurobiol Dis; 2021 Jul; 155():105374. PubMed ID: 33940179
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice.
    Chu-LaGraff Q; Kang X; Messer A
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):307-12. PubMed ID: 11719265
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease.
    DeMarch Z; Giampà C; Patassini S; Bernardi G; Fusco FR
    Neurobiol Dis; 2008 Jun; 30(3):375-387. PubMed ID: 18424161
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neuroprotective effects of hepatoma-derived growth factor in models of Huntington's disease.
    Voelkl K; Gutiérrez-Ángel S; Keeling S; Koyuncu S; da Silva Padilha M; Feigenbutz D; Arzberger T; Vilchez D; Klein R; Dudanova I
    Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37580082
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.
    Gil JM; Leist M; Popovic N; Brundin P; Petersén A
    BMC Neurosci; 2004 May; 5():17. PubMed ID: 15134587
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Alleviation of Huntington pathology in mice by oral administration of food additive glyceryl tribenzoate.
    Dutta D; Majumder M; Paidi RK; Pahan K
    Neurobiol Dis; 2021 Jun; 153():105318. PubMed ID: 33636386
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
    Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
    Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
    Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
    Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression.
    Couly S; Carles A; Denus M; Benigno-Anton L; Maschat F; Maurice T
    Neuropharmacology; 2021 Mar; 186():108467. PubMed ID: 33516737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.